Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Pancreatic Neoplasms × mitazalimab × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1 Pancreatic Ductal Adenocarcinoma 1 Biliary Tract Neoplasms 1

Interventions

Gemcitabine 405 Oxaliplatin 130 Fluorouracil 124 130-nm albumin-bound paclitaxel 108 Capecitabine 100 Albumin-Bound Paclitaxel 90 Leucovorin 87 Irinotecan 86 Radiotherapy 76 Taxes 64 Radiosurgery 63 Cisplatin 55 Erlotinib Hydrochloride 44 Drug Therapy 41 folfirinox 40 Magnetic Resonance Spectroscopy 37 pembrolizumab 35 Blood Specimen Collection 32 S 1 (combination) 31 Pancreaticoduodenectomy 31 Docetaxel 31 Nivolumab 30 Bevacizumab 29 Surgical Procedures, Operative 25 Cyclophosphamide 25 Biopsy 25 irinotecan sucrosofate 24 Specimen Handling 22 Radiation 22 Standard of Care 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05650918 2023-10-12

REACtiVe-2

Erasmus Medical Center

Phase 1 Completed

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡